id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323216-rgj8vs9z	Plotkin, Stanley A	Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2	2020-08-03		.txt	text/plain	970	63	51	There is a universal and widely acknowledged need for a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of its widespread circulation and high mortality and morbidity. Although some vaccine efforts use the whole inactivated or attenuated virus, the great majority concentrate on the Spike protein, which contains 2 parts: S1 and S2. Table 1 summarizes the current approaches to development of vaccines against SARS-CoV-2. Vaccine developers have experimented with many different ways to present the S protein or, in some cases, the RBD domain to the immune system. There are many important issues that must be answered in these trials, including: Can vaccination prevent infection as well as disease? Will evolution of the SARS-CoV-2 virus require changes in vaccine antigens? Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry The challenges of vaccine development against a new virus during a pandemic	./cache/cord-323216-rgj8vs9z.txt	./txt/cord-323216-rgj8vs9z.txt